XML 53 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Share-based Compensation (Tables)
9 Months Ended
Mar. 31, 2022
Share-based Compensation  
Schedule of weighted average assumptions

​

​

​

​

​

​

​

​

Nine Months Ended

​

​

March 31, 2021

Risk-free interest rate

​

​

0.2

%

Expected volatility

​

​

82.5

%

Expected dividend yield

​

​

—

%

Forfeiture rate

​

​

—

%

Expected term

​

​

5.0

years

Weighted average fair value

​

$

3.86

​

Summary of stock option award activity

​

​

​

​

​

​

​

​

​

​

​

​

​

    

    

    

​

​

    

​

​

    

Weighted

​

​

​

​

Weighted-

​

​

​

​

Average

​

​

​

​

Average

​

Aggregate

​

Remaining

​

​

​

​

Exercise

​

Intrinsic

​

Contractual

(In thousands, except for weighted average price and life data)

    

Awards

    

Price

    

Value

    

Life (yrs.)

Outstanding at June 30, 2021

 

1,046

​

$ 

9.51

​

$

25

​

7.2

Exercised

 

(3)

​

$ 

3.55

​

$

2

​

​

Forfeited, expired or repurchased

 

(96)

​

$ 

15.24

​

​

​

​

​

Outstanding at March 31, 2022

 

947

​

$ 

8.95

​

$

—

​

6.6

​

​

​

​

​

​

​

​

​

​

​

Vested and expected to vest at March 31, 2022

 

947

​

$ 

8.95

​

$

—

​

6.6

Exercisable at March 31, 2022

 

542

​

$ 

10.95

​

$

—

​

5.8

​

Summary of non-vested restricted stock awards

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted

​

​

​

​

​

​

​

Average Grant -

​

Aggregate

(In thousands, except for weighted average price data)

    

Awards

    

date Fair Value

    

Intrinsic Value

Non-vested at June 30, 2021

 

1,350

​

$

6.75

​

​

​

Granted

 

1,110

​

 

4.14

​

​

​

Vested

 

(1,000)

​

 

5.97

​

$

3,788

Forfeited

 

(90)

​

 

5.66

​

​

​

Non-vested at March 31, 2022

 

1,370

​

$

5.28

​

​

​

​

Schedule of non-vested performance-based shares

​

​

​

​

​

​

​

​

​

​

​

​

Weighted

​

​

​

​

​

Average Grant -

​

(In thousands, except for weighted average price and life data)

    

Awards

    

date Fair Value

    

Non-vested at June 30, 2021

 

531

​

$

10.29

​

Granted

 

617

​

$

6.04

​

Performance adjustment (1)

​

(40)

​

$

17.69

​

Vested

 

(58)

​

$

7.72

​

Non-vested at March 31, 2022

 

1,050

​

$

7.65

​

(1)Represents the adjustment based on the performance of the July 2018 awards, which was below the Threshold goal level at the end of the three-year performance period.
Schedule of allocation of share-based compensation

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

​

March 31, 

​

March 31, 

​

(In thousands)

    

2022

    

2021

    

2022

    

2021

​

Selling, general and administrative expenses

​

$

1,501

​

$

1,411

​

$

6,313

​

$

5,632

​

Research and development expenses

​

 

29

​

 

132

​

 

151

​

 

419

​

Cost of sales

​

 

169

​

 

320

​

 

562

​

 

1,145

​

Total

​

$

1,699

​

$

1,863

​

$

7,026

​

$

7,196

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Tax benefit at statutory rate

​

$

382

​

$

419

​

$

1,581

​

$

1,619

​